Eyes open to stem cells: safety trial may pave the way for cell therapy to treat retinal disease in patients

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

A clinical trial using human embryonic stem cell (hESC) therapy for an inherited retinal degenerative disease is about to commence. The Advanced Cell Technology (ACT) trial will treat patients with Stargardt's macular dystrophy using transplanted retinal pigment epithelium derived from hESCs. Currently, no effective treatment is available for Stargardt's disease so a stem cell-based therapy that can slow progression of this blinding condition could represent a significant breakthrough. While there are some hurdles to clear, the ACT trial is a fine example of translational research that could eventually pave the way for a range of stem cell therapies for the retina and other tissues.
Original languageEnglish
Article number47
Pages (from-to)47-50
Number of pages4
JournalStem Cell Research & Therapy
Volume2
Issue number6
DOIs
Publication statusPublished - 2011

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology (miscellaneous)
  • Cell Biology
  • Molecular Medicine
  • Medicine(all)
  • Medicine (miscellaneous)

Fingerprint Dive into the research topics of 'Eyes open to stem cells: safety trial may pave the way for cell therapy to treat retinal disease in patients'. Together they form a unique fingerprint.

Cite this